This study compared differences in weight loss, comorbidity resolution and complications and reoperations between a recently established sleeve gastrectomy (SG) and prior laparoscopic Rox-en-Y gastric bypass (RYGB).
This retrospective study with prospectively collected registry data presents results from establishment of SG as standard procedure for morbid obesity. Our first 368 patients operated with a SG were compared to 647 patients previously operated with a (RYGB. Perioperative data and results up to 2 years postoperatively regarding weight control, metabolic control as well as complications/reoperations necessary were registered. In summary, a RYGB was associated with a longer operation time and higher rates of late complications and reoperations. Diabetes resolution was similar in both groups but patients with a RYGB had greater weight loss and significant improvement in hypertension and dyslipidemias.
Study Type
OBSERVATIONAL
Enrollment
1,015
operation type differed between a partial gastrectomy (SG)or a combined restrictive/malabsorptive
Sundsvall Hospital
Sundsvall, Sweden
Weight loss
weight and height will be combined to report various measurements of BMI in kg/m\^2
Time frame: after 6 weeks
Weight loss
weight and height will be combined to report various measurements of BMI in kg/m\^2
Time frame: after 1 year
Weight loss
weight and height will be combined to report various measurements of BMI in kg/m\^2
Time frame: after 2 years
Changes in Diabetes
measured as fasting plasma glucose and/or Hemoglobin A1c
Time frame: after 1 year
Changes in Diabetes
measured as fasting plasma glucose and/or Hemoglobin A1c
Time frame: after 2 years
Changes in Hypertension
measured as Systolic- and Diastolic Blood Pressure
Time frame: after 1 year
Changes in Hypertension
measured as Systolic- and Diastolic Blood Pressure
Time frame: after 2 years
Changes in hypertriglyceridemia (plasma-level >1.7 mmol/l)
measured as hypertriglyceridaemia (plasma-level \>1.7 mmol/l)
Time frame: after 1 year
Changes in hypertriglyceridemia (plasma-level >1.7 mmol/l)
measured as hypertriglyceridaemia (plasma-level \>1.7 mmol/l)
Time frame: after 2 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Changes in Hypercholesterolemia (LDL-C > 3.0 mmol/L and/or HDL-C < 1.0 mmol/L).
Measured as Hypercholesterolemia (Plasma concentration of LDL \>3.0 mmol/L and/or of HDL \< 1.0 mmol/L).
Time frame: after 1 years
Changes in Hypercholesterolemia (LDL-C > 3.0 mmol/L and/or HDL-C < 1.0 mmol/L).
Measured as Hypercholesterolemia (Plasma concentration of LDL \>3.0 mmol/L and/or of HDL \< 1.0 mmol/L).
Time frame: after 2 years
Duration of surgery
Operation time in minutes
Time frame: From the start of the operation until completion, in average 62 minutes
Duration of hospital stay
Duration of hospital stay in days
Time frame: From time of operation until discharge, in average 1.7 days
Early complications
Complications occurred until six weeks from operation
Time frame: At six weeks
Early reoperations
Reoperations occurred until six weeks from operation
Time frame: At six weeks
Late complications
Complications occurred from six weeks until 2 years from operation
Time frame: From six weeks until 2 years from operation
Late reoperations
Reoperations occurred from six weeks until 2 years from operation
Time frame: From six weeks until 2 years from operation